Polycystic ovary syndrome: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• GLP-1 5
• PI3K 0
• AKT 0
• IL-6 0
• AMPK 0
• mTOR 0
• TNF 1
• PPAR 0
• NLRP3 0
• SIRT1 0
• NRF2 0
• STAT3 0
• TLR4 0
• AR 0
• TP53 0
• VEGF 0
• MAPK 0
• COX-2 0
• ERK 0
• ESR1 0
• IL-1 0
• BCL-2 0
• DPP-4 0
• GIP 0
• GPX4 0
• HMGB1 0
• JAK 0
• PINK1 0
• PTEN 0
• BDNF 0
• BRD4 0
• CD40 0
• EGFR 0
• IGF1R 0
• MMP-9 0
• PCSK9 0
• SGLT2 0
• STING 0
• STK11 0
• TERT 0
• BRCA1 0
• CTNNB1 0
• FTO 0
• HDAC 0
• HSP90 0
• IL-17 0
• JNK 0
• KIT 0
• METTL3 0
• NF1 0
• PARP 0
• PD-1 0
• PD-L1 0
• PDE4 0
• PKM2 0
• PNPLA3 1
• SHP2 0
• SOD1 0
• TREM2 0
• YAP 0

2+ intézményből 2, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NICHD · R61

  Toll-Like Receptor 4 Antagonism for Infertility Management in Polycystic Ovary Syndrome

  University of California-Irvine· Irvine, Egyesült Államok· 435 691 USD awarded in fiscal year 2026· until 2028. jún.

• NIH OD · OT2

  Computational Modeling of Female Hormone Homeostasis and Drug Responses

  Henry Ford Health + Michigan State University Health Sciences· East Lansing, Egyesült Államok· 4 587 853 USD awarded in fiscal year 2026· until 2027. szept.

• NIH NIA · R01

  Reproductive events, menopause and biological aging among Latina women

  Emory University· Atlanta, Egyesült Államok· 720 040 USD awarded in fiscal year 2026· until 2031. ápr.

• NIH NICHD · R01

  Mechanisms and Therapeutic Potential of MKRN3 in the Neuroendocrine Regulation of Puberty and Reproduction

  Boston Children's Hospital· Boston, Egyesült Államok· 692 296 USD awarded in fiscal year 2026· until 2031. máj.

• NIH NICHD · R01

  Metformin for gestational diabetes: assessing risk of long-term childhood outcomes

  Rutgers Biomedical and Health Sciences· Newark, Egyesült Államok· 718 484 USD awarded in fiscal year 2026· until 2031. jún.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Elucidating the role of maternal nutrient stores in the metabolism of the preimplantation embryo (MaterMeta)

  Kobenhavns Universitet· Kobenhavn, Dánia· EU contribution 247 553 EUR· until 2029. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Cell type-specific endometrial dysfunctions across the menstrual cycle and their potential for drug interventions in polycystic ovary syndrome (POTRET)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 236 340 EUR· until 2028. júl.

• European Commission (Horizon 2020) · RIA

  PCOS IN ADOLESCENT GIRLS AND YOUNG WOMEN: TOWARD A TREATMENT GUIDED BY PATHOPHYSIOLOGY (SPIOMET4HEALTH)

  Fundacio Privada Per A la Recerca I la Docencia Sant Joan de Deu· Esplugues De Llobregat, Spanyolország· EU contribution 6 366 149 EUR· until 2026. dec.· 9 countries

8 of 74 running projects, newest first. Listed amounts together: 37,7 M USD + 6,9 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)

  NCT07169136· Nemours Children's Clinic· Forrás

• Efficacy of a GLP-1/FGF21 Dual Agonist for Treating PCOS

  NCT07616037· Shanghai Zhongshan Hospital· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 9
• Organoids 4
• Mendelian Randomization Analysis 23
• CRISPR-Cas Systems 1
• Gene Expression Profiling 19
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 1
• Proteomics 13
• Metabolomics 22
• Mass Spectrometry 4
• Flow Cytometry 3
• Immunohistochemistry 6
• Magnetic Resonance Imaging 9
• Machine Learning 24
• Deep Learning 6
• Cohort Studies 75
• Genome-Wide Association Study 35

• Amniotic-fluid metabolomics identifies phospholipid remodeling as a metabolic signature of intrauterine exposure in pregnancies with polycystic ovary syndrome.

  Front Endocrinol (Lausanne), 2026. szept.

• Elucidating the Molecular Mechanisms of Vitex negundo L. in Polycystic Ovary Syndrome via Metabolomics-Driven Network Pharmacology.

  Biomed Chromatogr, 2026. szept.

• Metabolic Stress Testing Reveals Persistent Lipid-Handling Dysfunction in Women With Polycystic Ovary Syndrome Despite Exercise Training.

  Diabetes Obes Metab, 2026. aug.

• Metabolic profiling of human follicular fluid to unravel the pathways involved in polycystic ovary syndrome - a systematic review.

  Rev Endocr Metab Disord, 2026. júl.

• Type 2 diabetes and obesity in South Asian patients with polyendocrine metabolic ovarian syndrome: The emerging role of metabolomics.

  Best Pract Res Clin Endocrinol Metab, 2026. máj.

• PCOS combined with obesity aggravates the metabolic and immune abnormality in females.

  BMC Womens Health, 2026. ápr.

• Multi-Target Modulation of Metabolic and Steroidogenic Pathways by Cinnamomum burmannii and Myristica fragrans in Polycystic Ovary Syndrome: An Integrative Transcriptomics, Metabolomic, Pharmacoinformatics and Experimental Validation.

  Nutrients, 2026. ápr.

• Integrative metabolomics and machine learning reveal the toxic mechanisms of elaidic acid in polycystic ovary syndrome.

  Reprod Toxicol, 2026. febr.

• Investigating the "homotherapy for heteropathy" mechanism of Danggui Shaoyao San in Alzheimer's disease and polycystic ovary syndrome via MAPK signaling pathway and metabolomics.

  J Ethnopharmacol, 2026. febr.

• Metabolomic profiling of follicular fluid reveals unique pathways in endometriosis and infertility etiologies: a pilot study.

  PeerJ, 2026. febr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.